Drug intelligence / Profile preview

nortriptyline + topiramate

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

A combination of nortriptyline, a tricyclic antidepressant, and topiramate, an antiseizure medication, used primarily for migraine prevention. This combination is particularly effective in patients who have had incomplete relief with either agent alone. Nortriptyline works by inhibiting the reuptake of serotonin and norepinephrine, while topiramate influences GABA and glutamate receptors to act on cortical hyperexcitability.

Targets

GABRR (GABA-A receptor subunit rho)iGluR (Ionotropic receptor 76b (Ir76b))HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))NET (Norepinephrine Transporter)HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on nortriptyline + topiramate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nortriptyline + topiramate.

Explore the full profile